Getein Biotech, Inc

Equities

603387

CNE100002RR9

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
9.48 ^CNY	0.00%		-3.76%	-13.82%

Apr. 29	Getein Biotech, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 29	Getein Biotech, Inc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Akang Health announced that it has received CNY 200 million in funding from China Science & Merchants Investment Management Group Co., Ltd., CICC Investment Group Company Limited, Getein Biotech, Inc, China Science and Tech Innovation Venture Capital Management, Nanjing Jidan Equity Investment Management Co., Ltd. and other investors

March 15, 2021

Akang Health announced that it has received CNY 200 million in its series B round of funding led by CICC Qide Innovative Biopharmaceutical Equity Investment Fund a fund managed by CICC Investment Group Company Limited on March 16, 2021. The transaction included participation from China Science and Tech Innovation Venture Capital Management, Tzitzit Aseet, Getein Biotech, Inc (SHSE:603387), Zero One Asset Management,China Science & Merchants Investment Management Group Co., Ltd., Zhongke Kechuang and Nanjing Bofu Investment and new investor Nanjing Jidan Equity Investment Management Co., Ltd.

Latest news about Getein Biotech, Inc

Getein Biotech, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Getein Biotech, Inc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
Getein Biotech, Inc Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Getein Biotech, Inc Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Getein Biotech, Inc Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Getein Biotech, Inc Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Meihua International Unit, Getein Biotech to Develop COVID-19 Antigen Test Kits, Other In Vitro Diagnostic Products	23-01-11	MT
Meihua International Medical Technologies Co., Ltd. Enters into Strategic Partnership with Getein Biotech Inc. to Jointly Produce and Sell Covid-19 Antigen Test Kits and IVDs	23-01-11	CI
Getein Biotech Gets Regulatory Approval for COVID-19 Kit; Shares Up 9%	22-12-12	MT
Getein Biotech, Inc Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Yestar Healthcare, Getein Biotech End Investment Talks	22-08-24	MT
Getein Biotech, Inc Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-23	CI
Yestar Healthcare Holdings Company Limited cancelled the transaction announced on April 8, 2022	22-08-22	CI
Getein Biotech, Inc Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Yestar Healthcare Holdings Company Limited announced that it expects to receive funding from Getein Biotech, Inc	22-04-07	CI
Getein Biotech, Inc Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-11	CI
Sichuan Getein Biotechnology Co., Ltd. announced that it expects to receive CNY 30 million in funding from Getein Biotech, Inc	22-02-23	CI
Getein Biotech, Inc Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-27	CI
Getein Biotech, Inc Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-17	CI
Tranche Update on Getein Biotech, Inc's Equity Buyback Plan announced on December 31, 2020.	21-06-29	CI
Getein Biotech, Inc's Equity Buyback announced on December 30, 2020, has expired with 1,560,790 shares, representing 0.43% for CNY 50 million.	21-06-28	CI
KK Culture : Unit Seals COVID-19 Kits Distribution Deal with Getein Biotech; Shares Slump 11%	21-05-26	MT
Getein Biotech, Inc Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-27	CI
Tranche Update on Getein Biotech, Inc's Equity Buyback Plan announced on December 31, 2020.	21-04-01	CI
Akang Health announced that it has received CNY 200 million in funding from China Science & Merchants Investment Management Group Co., Ltd., CICC Investment Group Company Limited, Getein Biotech, Inc, China Science and Tech Innovation Venture Capital Management, Nanjing Jidan Equity Investment Management Co., Ltd. and other investors	21-03-15	CI

Chart Getein Biotech, Inc

Duration

Period

More charts

Company Profile

Getein Biotech Inc is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. Its in vitro diagnostic reagents include Point-of-care Testing (POCT) reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, hemagglutination reagents and others. Its diagnostic instruments include immunoquantitative analyzer FIA 8000, immunoquantitative analyzer FIA 8600, fluorescence immunoquantitative analyzer Getein 1100, fluorescence immunoquantitative analyzer Getein 1180, automatic biochemical analyzer CM 400, automatic chemiluminescence analyzer MAGICL 6000 and five classification blood cell analyzer BHA-5000, among others. The Company also provides testing and agency services. The Company distributes its products within domestic market and to overseas markets.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-22 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
GETEIN BIOTECH, INC	-13.82%	666M
BIOMÉRIEUX	-4.57%	12.32B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-4.35%	8.1B
DIASORIN S.P.A.	+8.91%	5.87B
LANTHEUS HOLDINGS, INC.	+30.69%	5.52B
AUTOBIO DIAGNOSTICS CO., LTD.	-7.42%	4.29B
10X GENOMICS, INC.	-54.11%	3.16B
ANDON HEALTH CO., LTD.	+14.44%	2.72B
VITROLIFE AB	-2.21%	2.37B
MYRIAD GENETICS, INC.	+29.62%	2.23B

Diagnostic & Testing Substances